Gland Pharma Limited has scheduled a meeting of its Board of Directors for May 15, 2026. During this session, the board will review the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. Additionally, the company will discuss the potential recommendation of a Final Dividend for the 2025-26 fiscal year.
Financial Results and Dividend Review
The upcoming board meeting, set for May 15, 2026, will focus on the company’s financial performance. Directors are slated to approve the audited financial results covering the fourth quarter and the full financial year 2025-26. A key highlight of the agenda is the consideration and potential recommendation of a Final Dividend for shareholders for the fiscal year.
Trading Window Update
In accordance with internal governance policies, the company has maintained a restricted trading window for its securities. The window, which has been closed since March 28, 2026, is scheduled to reopen on May 18, 2026, following the conclusion of the board meeting and the disclosure of the financial results.
Investor Engagement
To ensure transparency regarding the upcoming financial disclosures, Gland Pharma will host an Investor/Analyst call on May 15, 2026, at 18:30 Hrs (IST). This session will provide stakeholders with an opportunity to gain insights into the annual performance and the strategic outlook for the company following the fiscal year-end.
Source: BSE
